Dimensional Fund Advisors LP Has $57.57 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dimensional Fund Advisors LP boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,611,743 shares of the company's stock after purchasing an additional 313,817 shares during the period. Dimensional Fund Advisors LP owned approximately 0.23% of Teva Pharmaceutical Industries worth $57,568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. FMR LLC lifted its holdings in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $58,243,000. Marshall Wace LLP grew its stake in Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after purchasing an additional 2,410,420 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $38,914,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 3.8 %

Shares of NYSE TEVA traded up $0.60 during mid-day trading on Friday, reaching $16.22. 11,919,719 shares of the company traded hands, compared to its average volume of 9,977,348. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market cap of $18.39 billion, a PE ratio of -11.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company's fifty day moving average is $15.11 and its two-hundred day moving average is $17.49.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.